Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Suvorexant

FDA-approved product (tablet, oral), marketed as Belsomra.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Suvorexant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Orexin receptor antagonists
FDA pharmacologic class
Orexin Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Suvorexant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Suvorexant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)

    NCT01293006 · start 2011-03-25

    Registered record
    Registry ID
    NCT01293006
    Conditions
    Insomnia
    Interventions
    suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-03-25
    Completion
    2012-02-22
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    Interventionsuvorexant; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)

    NCT01059851 · start 2010-05-24

    Registered record
    Registry ID
    NCT01059851
    Conditions
    Insomnia
    Interventions
    Suvorexant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-05-24
    Completion
    2010-07-15
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionSuvorexant
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)

    NCT01097616 · start 2010-05-05

    Registered record
    Registry ID
    NCT01097616
    Conditions
    Primary Insomnia
    Interventions
    Suvorexant High Dose (HD); Suvorexant Low Dose (LD); Comparator: Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-05-05
    Completion
    2011-12-07
    Enrolment
    1,023

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Insomnia
    InterventionSuvorexant High Dose (HD); Suvorexant Low Dose (LD); Comparator: Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)

    NCT01021813 · start 2009-12-10

    Registered record
    Registry ID
    NCT01021813
    Conditions
    Insomnia
    Interventions
    Suvorexant; Dose-matched Placebo to Suvorexant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-12-10
    Completion
    2011-08-01
    Enrolment
    781

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionSuvorexant; Dose-matched Placebo to Suvorexant
    PhasePhase 3
    Registry statusCompleted

  • Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)

    NCT00792298 · start 2008-11-05

    Registered record
    Registry ID
    NCT00792298
    Conditions
    Primary Insomnia
    Interventions
    Suvorexant; Dose-matched Placebo to Suvorexant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11-05
    Completion
    2009-12-26
    Enrolment
    254

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Insomnia
    InterventionSuvorexant; Dose-matched Placebo to Suvorexant
    PhasePhase 2
    Registry statusCompleted